Under the deal, Abzena’s CDMO facilities in Bristol, Penn. and San Diego will be supplied with Sartorius Stedim Biotech equipment. Sartorius Stedim will supply end-to-end process solutions in single-use format.
“We are pleased to have been selected by Abzena, a prominent global CDMO with a comprehensive industry portfolio across a wide range of modalities to supply single-use solutions that enable process development, tech transfer and GMP manufacturing. We look forward to working together to best serve the US and international markets,” Reinhard Vogt, executive VP of Sartorius, said.
The San Diego facility develops and manufactures monoclonal antibodies and other recombinant proteins. It will receive Ambr250 to enable fast scale up to 500L at first and then 2000L scale single-use bioreactor for its center of excellence in clinical manufacturing.
“In addition to having selected Sartorius’ industry leading single-use technologies for antibody and ADC production, the Abzena facilities will feature Umetrics process analytics software throughout the process ensuring that all the data captured throughout our clients’ molecule development is transformed into process knowledge ensuring that we can rapidly develop a robust and reliable process that can be easily scaled up to ensure a smooth technology transfer,”John Burt, CEO of Abzena, said.